Milestone Pharmaceuticals MIST 深 滬
等待開盤 07-18 09:30:00 美东时间
1.65
-0.020
-1.20%
華盛通- 最 高1.71
- 今 開1.69
- 成交量 202.04万股
- 最 低 1.5901
- 昨 收 1.67
- 總市值 8821.61万
- 52周最高 2.75
- 市盈率 靜 --
- 換手率 3.78%
- 52周最低 0.6254
- 委 比 -51.33%
- 總股本 5346.43万
- 歷史最高 27.95
- 量 比 0.27
- 振 幅 7.18%
- 歷史最低 0.6254
- 每 手 1
- 風險率 0.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Is Milestone Pharmaceuticals Stock Plunging On Friday?
FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $52.5 million to support potential PSVT treatment launch.
07-12 00:22
Milestone Pharmaceuticals plunges after pricing $52.5M offering
Milestone Pharmaceuticals (NASDAQ:MIST) shares fell nearly 38% on Friday after the company priced an offering to raise approximately $52.5 million. The offering includes 31.5 million common shares wit...
07-11 22:41
Milestone Pharma Prices $52.5M Equity Offering With Warrants; Offering Is Expected To Close On Or About July 14, 2025
Milestone® Pharmaceuticals Inc. ("Milestone") (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its
07-11 21:34
Milestone says heart disorder therapy under FDA review again
Milestone Pharmaceuticals (NASDAQ:MIST) announced on Friday that the U.S. FDA accepted for review its responses to the rejection letter sent early this year regarding its marketing application for its...
07-11 19:34
Milestone Pharmaceuticals proposes capital raise via securities offering
Milestone Pharmaceuticals (NASDAQ:MIST) has launched a public offering to raise capital, that includes common shares, alongside both Series A and Series B warrants. For certain, investors will have th...
07-11 18:34
Milestone Pharmaceuticals Amends Royalty Agreement with RTW
Milestone Pharmaceuticals ( ($MIST) ) has issued an announcement. On July 10, 2...
07-11 18:28
Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants
Milestone Pharmaceuticals announced the pricing of its public offering, raising approximately $52.5 million. The offering includes 31.5 million common shares and accompanying warrants, with proceeds to fund clinical development and commercial launch of etripamil for treating paroxysmal supraventricular tachycardia (PSVT). The offering is expected to close on July 14, 2025.
07-11 13:30
Milestone Pharmaceuticals Announces Proposed Public Offering
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) has announced the commencement of an underwritten public offering of its common shares, Series A warrants, Series B warrants, and pre-funded warrants, with the proceeds intended for the clinical development and commercial launch of its drug etripamil for the treatment of paroxysmal supraventricular tachycardia (PSVT), as well as general corporate purposes. The offering is expected to be made under a p...
07-11 10:01
当代综合战力天花板！上手体验掠夺者·战斧18 AI旗舰电竞本
【ZOL中关村在线原创评测】在顶级游戏本品牌中，宏碁旗下的掠夺者·战斧系列一直以来有着极为扎实的表现。出色的性能调校、家族传承的设计语言、以及每一代新品几乎都会...
07-01 06:52
MISTRAS Group Names Cody Elliott Vice President of Pipeline Data Solutions
MISTRAS Group appoints Cody Elliott as Vice President of Pipeline Data Solutions, leveraging his 15 years of industry experience to drive growth in inline inspection and data solutions. Elliott will lead the company’s advanced pipeline integrity services, integrating technologies to help clients enhance safety, compliance, and operational efficiency. His expertise will support MISTRAS’ end-to-end asset integrity solutions across North America.
06-25 13:00
